^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | liposomal annamycin (L-ANN) (DNA topoisomerase inhibitor, Topoisomerase II-alpha inhibitor, Topoisomerase II-beta inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin
Published date:
04/18/2019
Excerpt:
Moleculin Biotech, Inc...announced that the U.S. Food and Drug Administration (FDA) has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia (AML).
